ProCE Banner Activity

IMerge: Phase III Trial of Imetelstat vs Placebo for Transfusion-Dependent Lower-Risk MDS Relapsed/Refractory to ESAs

Conference Coverage
Slideset

Imetelstat significantly increased transfusion independence at 8 weeks compared with placebo in patients with transfusion-dependent lower-risk MDS relapsed/refractory to ESAs, with durable responses reported among those achieving transfusion independence at 8 weeks.

Released: June 06, 2023

Share

Provided by

Provided by Clinical Care Options, LLC.

ProCE Banner

Supporters

Supported by educational grants from AbbVie, Geron, Jazz Pharmaceuticals, Lilly, Merck Sharp & Dohme Corp., and Novartis.

AbbVie

Geron

Jazz Pharmaceuticals

Lilly

Merck Sharp & Dohme Corp.

Novartis